MedTrace Logo

HRT on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness

NCT05280028 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-06-17

No results posted yet for this study

Summary

Therefore, the aim of this study is to assess the therapeutic effect on overactive bladder symptoms, sexual function, heart rate variability, arterial stiffness, atherosclerosis, sleep, and depression between tibolone and E2V/MPA.

From the results, the investigators will compare the effect of tibolone versus E2V/MPA on overactive bladder symptoms, sexual function, autonomic function, arterial stiffness, atherosclerosis, sleep and depression.

Conditions

  • Menopausal Syndrome

Interventions

DRUG

Tibolone 2.5 mg

Tibolone 2.5 mg per day

DRUG

Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg

Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg per day

Sponsors & Collaborators

  • Far Eastern Memorial Hospital

    lead OTHER

Principal Investigators

  • Sheng-Mou Hsiao, MD · Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-07
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05280028 on ClinicalTrials.gov